Pharmacogenomics of biological treatment in rheumatoid arthritis

Bibliography

• Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
   PubMed Web of Science ®Google Scholar
• Barnabe C, Hanley DA. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009;39:116-22
   PubMed Web of Science ®Google Scholar
• Keystone EC. Strategies to control disease in rheumatoid arthritis with tumor necrosis factor antagonists-an opportunity to improve outcomes. Nat Clin Pract Rheumatol 2006;2:594-601
   PubMedGoogle Scholar
• Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:778-87
   PubMed Web of Science ®Google Scholar
• Canhao H, Rodrigues AM, Mourao AF, et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 2012;51:2020-6
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
   PubMed Web of Science ®Google Scholar
• Wada T, Son Y, Ozaki Y, et al. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis. Mod Rheumatol 2012;22:824-30
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177-85
   PubMed Web of Science ®Google Scholar
• Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17:3532-8
   PubMed Web of Science ®Google Scholar
• Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007;57:1426-30
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmuller U, Moller B, et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007;46:93-6
   PubMed Web of Science ®Google Scholar
• Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6
   PubMed Web of Science ®Google Scholar
• Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:547-52
   PubMed Web of Science ®Google Scholar
• Padyukov L, Lampa J, Heimburger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9
   PubMed Web of Science ®Google Scholar
• Schotte H, Schluter B, Drynda S, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:575-81
   PubMed Web of Science ®Google Scholar
• Tam LS, Shang Q, Li EK, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis – a randomized trial. J Rheumatol 2012;39:2267-75
   PubMed Web of Science ®Google Scholar
• Taylor PC, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 2006;54:47-53
   PubMed Web of Science ®Google Scholar
• Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9
   PubMed Web of Science ®Google Scholar
• Fonseca JE, Carvalho T, Cruz M, et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005;64:793-4
   PubMed Web of Science ®Google Scholar
• Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52
   PubMed Web of Science ®Google Scholar
• Cuchacovich M, Ferreira L, Aliste M, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 2004;33:228-32
   PubMed Web of Science ®Google Scholar
• Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077-82
   PubMed Web of Science ®Google Scholar
• Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006;65:342-7
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A, Georgiou I, Voulgari PV, et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007;46:1034-5
   PubMed Web of Science ®Google Scholar
• Cuchacovich M, Soto L, Edwardes M, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol 2006;35:435-40
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008;67:478-84
   PubMed Web of Science ®Google Scholar
• Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52:2693-6
   PubMed Web of Science ®Google Scholar
• Lee YH, Rho YH, Choi SJ, et al. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006;27:157-61
   PubMed Web of Science ®Google Scholar
• O'Rielly DD, Roslin NM, Beyene J, et al. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 2009;9:161-7
   PubMed Web of Science ®Google Scholar
• Pavy S, Toonen EJ, Miceli-Richard C, et al. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010;69:1022-8
   PubMed Web of Science ®Google Scholar
• Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008;14:575-81
   PubMed Web of Science ®Google Scholar
• Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011;63:645-53
   PubMed Web of Science ®Google Scholar
• Krintel SB, Palermo G, Johansen JS, et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 2012;22:577-89
   PubMed Web of Science ®Google Scholar
• Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 2013;9:e1003394
   PubMed Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013;15(Suppl 1):S3
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2012;71:875-7
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Pontarini E, et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis 2013 .[Epub ahead of print]
   Google Scholar
• Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14
   PubMed Web of Science ®Google Scholar
• Sarsour K, Greenberg J, Johnston JA, et al. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-alpha antagonist therapies. Clin Exp Rheumatol 2013;31:189-94
   PubMed Web of Science ®Google Scholar
• Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013;131:959-71
   PubMed Web of Science ®Google Scholar
• Ruyssen-Witrand A, Rouanet S, Combe B, et al. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 2013;52:636-41
   PubMed Web of Science ®Google Scholar
• Fabris M, Quartuccio L, Lombardi S, et al. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo 2010;62:253-8
   PubMedGoogle Scholar
• Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768-80
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2013 ; doi: 10.1136/annrheumdis-2013-203523
   Web of Science ®Google Scholar
• Nishimoto N, Amano K, Hirabayashi Y, et al. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheumatol 2013 . [Epub ahead of print]
   PubMedGoogle Scholar
• Suzuki T, Horikoshi M, Sugihara M, et al. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Mod Rheumatol 2013;23:782-7
   PubMed Web of Science ®Google Scholar
• Wang J, Bansal AT, Martin M, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2013;13:235-41
   PubMed Web of Science ®Google Scholar
• Vicente Rabaneda EF, Herrero-Beaumont G, Castaneda S. Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2013;9:599-621
   PubMed Web of Science ®Google Scholar
• Atzeni F, Puttini PS, Mutti A, et al. Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 2013;12:1115-7
   PubMed Web of Science ®Google Scholar
• Horak P, Skacelova M, Hejduk K, et al. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clin Rheumatol 2013;32:1451-8
   PubMed Web of Science ®Google Scholar
• Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013;52:986-97
   PubMed Web of Science ®Google Scholar
• Genovese MC, Schiff M, Luggen M, et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012;39:1546-54
   PubMed Web of Science ®Google Scholar